| Nov 18 |
Evaxion Biotech files for offering of ADSs
|
| Nov 13 |
Evaxion receives delisting determination from Nasdaq
|
| Nov 13 |
Evaxion receives and appeals delisting determination from Nasdaq, remains committed to Nasdaq listing
|
| Nov 12 |
EVAX Racks up Positive Test Results
|
| Nov 12 |
Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1
|
| Oct 31 |
Evaxion Biotech ADS GAAP EPS of -$0.04, revenue of $3.01M
|
| Oct 31 |
Evaxion announces business update and third quarter 2024 financial results
|
| Oct 31 |
EVAX Exceeds Estimates and Confirms Partnership
|
| Oct 28 |
Evaxion to announce business update and third quarter 2024 financial results on October 31
|
| Oct 11 |
OTC Markets Hosts Virtual Investor Presentation with Christian Kanstrup, CEO of Evaxion Biotech, and Brad Sorensen, Senior Analyst at Zacks SCR
|
